Lisa Deschamps
Direktor/Vorstandsmitglied bei VERONA PHARMA PLC
Vermögen: 848 762 $ am 31.05.2024
Ursprung des Netzwerks ersten Grades von Lisa Deschamps
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
The Leonard N Stern School of Business
233
| College/University | Other Consumer Services | 233 |
Public Company | Pharmaceuticals: Major | 24 | |
21
| Extinct | Biotechnology | 21 |
Iona College
16
| College/University | Other Consumer Services | 16 |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021.
10
| Holding Company | Biotechnology | 10 |
Reset Pharmaceuticals, Inc.
Reset Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reset Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing and commercializing novel treatments for patients suffering from mental illness related to life-altering diseases. Reset Pharmaceuticals is based in Great Neck, NY and was founded by Philip Taub and Jan-Anders Karlsson. The company's lead product candidate, the oral psilocybin, is being developed to treat demoralization syndrome in patients with cancer. Reset Pharma has a highly experienced team with a strong track record of successful development, approvals, and launches of neuroscience drugs. The company also has a scientific advisory board of key opinion leaders in psychiatry, oncology, and psychedelics, as well as a strategic advisory board of business leaders and financial experts.
4
| Holding Company | Pharmaceuticals: Major | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Lisa Deschamps
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
INTERMUNE INC | Biotechnology | Corporate Officer/Principal Director/Board Member | |
UBS Securities LLC
UBS Securities LLC Investment ManagersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Managers | Analyst-Equity Analyst-Equity | |
JPMorgan Securities LLC
JPMorgan Securities LLC Investment ManagersFinance JPMorgan Securities LLC (JPMS) is a securities brokerage firm headquartered in New York City. The firm was founded in 1985 and is a subsidiary of JPMorgan Broker-Dealer Holdings, Inc., ultimately held by JPMorgan Chase & Co., Inc. (NYSE: JPM). JPMS provides research on fixed income, credit, derivatives, emerging markets, foreign exchange, structured finance, technical analysis and bond indices. Their equity analysts cover equities throughout North America, EMEA, Asia/Pacific and the emerging markets. The firm's fixed income team formulates trading and portfolio recommendations for investors in global bonds and other fixed-income markets based on valuations, analytics and market dynamics. | Investment Managers | Corporate Officer/Principal Analyst-Equity | |
Bayer Pharmaceuticals Corp. | Director of Finance/CFO Chief Tech/Sci/R&D Officer | ||
REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Investment Banks/Brokers | Analyst-Equity Corporate Officer/Principal Analyst-Equity Analyst-Equity | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
ZAVAROVALNICA TRIGLAV, D.D. | Multi-Line Insurance | Corporate Officer/Principal | |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Investment Banks/BrokersFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Investment Banks/Brokers | Analyst-Equity Economist Analyst-Fixed Income Analyst-Equity | |
Abanka dd
Abanka dd Regional BanksFinance Abanka dd engages in the provision of retail, corporate banking, and financing services. It operates through the following segments: Retail Banking, Corporate Banking, and Financial Markets. The Retail Banking segment provides banking accounts, internet, and mobile banking, credit cards, loans, and insurance services. The Corporate Banking segment offers deposits, guarantees, advances, and cash management services. The Financial Markets segment includes liquidity management, investment banking, interbank, and trading services. The company was founded in 1955 and is headquartered in Ljubljana, Slovenia. | Regional Banks | Director of Finance/CFO | |
Xention Pharma Ltd.
Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Barclays Capital, Inc.
Barclays Capital, Inc. Investment Banks/BrokersFinance Barclays Capital, Inc. is a registered broker/dealer headquartered in New York City. The firm was founded in 1997 and is a subsidiary of Barclays Group US, Inc., ultimately owned by Barclays plc (LON: BARC) in Great Britain. Barclays Capital provides large corporate, government and institutional clients a full spectrum of prime brokerage services which includes equities and fixed income financing, OTC Clearing, Futures and Foreign Exchange Prime Brokerage and access to industry insights and analytics from their Strategic Consulting team. | Investment Banks/Brokers | Analyst-Fixed Income Analyst-Fixed Income Analyst-Equity Analyst-Equity | |
University of Cambridge | College/University | Graduate Degree Masters Business Admin | |
Clemson University | College/University | Graduate Degree Undergraduate Degree | |
Temple University (Pennsylvania) | College/University | Undergraduate Degree Undergraduate Degree | |
Middlebury College | College/University | Undergraduate Degree | |
University of Wisconsin | College/University | Undergraduate Degree Undergraduate Degree | |
DOVA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer General Counsel Human Resources Officer Chief Tech/Sci/R&D Officer | |
University of Illinois | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
University of North Carolina at Chapel Hill | College/University | Graduate Degree Graduate Degree Doctorate Degree | |
Charm Therapeutics, Inc. | Director/Board Member Director/Board Member | ||
The Royal College of Physicians | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Biotechnology | Chairman Chief Tech/Sci/R&D Officer | |
Impresa Management LLC
Impresa Management LLC Investment ManagersFinance Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston. | Investment Managers | Private Equity Investor Private Equity Investor | |
RBC Capital Markets LLC
RBC Capital Markets LLC Investment Banks/BrokersFinance RBC Capital Markets LLC is a full-service brokerage and financial services firm headquartered in New York City. They are a direct subsidiary of RBC USA Holdco Corp. and a wholly-owned indirect subsidiary of Royal Bank of Canada (TSE, NYSE: RY). Founded in 2010, the firm is comprised of 3 major business lines: the Private Client Group, the Fixed-Income Group and the Clearing and Execution Services Group. The Private Client Group serves individual investors, while the Fixed-Income Group provides services to institutions, municipalities and non-profit organizations. The Clearing and Execution Services Group is a provider of clearing and execution services to independent brokers/dealers throughout the US. RBC Capital Markets focuses on the following sectors: communications, media, consumer/retail, diversified industries, energy, financial institutions, forest products, healthcare, infrastructure finance, mining & metals, real estate, social infrastructure, technology and the US municipal markets. | Investment Banks/Brokers | Corporate Officer/Principal Analyst-Equity | |
Charm Therapeutics Ltd.
Charm Therapeutics Ltd. BiotechnologyHealth Technology Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then. | Biotechnology | Director/Board Member Director/Board Member | |
University of Michigan | College/University | Undergraduate Degree Doctorate Degree | |
TAYSHA GENE THERAPIES, INC. | Biotechnology | Director/Board Member Chief Executive Officer | |
Jaguar Gene Therapy LLC
Jaguar Gene Therapy LLC Medical/Nursing ServicesHealth Services Jaguar Gene Therapy LLC is a company that aims to accelerate breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company is based in Lake Forest, IL. The company's unrelenting commitment is to advocate boldly and care fiercely for patients and families. The company works together to confront the challenges of treating complex diseases and are advancing their initial pipeline that targets diseases with significant unmet need in sizeable patient populations. Joseph Nolan has been the CEO of the company since 2020. | Medical/Nursing Services | Director of Finance/CFO Chairman | |
ADVERUM BIOTECHNOLOGIES, INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin | |
KD GROUP, FINANCNA DRUZBA, D. D. | Real Estate Development | Corporate Officer/Principal | |
Triglav INT, holdinška družba dd
Triglav INT, holdinška družba dd MiscellaneousMiscellaneous Part of Zavarovalnica Triglav dd, Triglav INT, holding družba dd is a company based in Ljubljana, Slovenia. The Slovene company operates as a holding company. | Miscellaneous | Corporate Officer/Principal | |
École des Hautes Études Commerciales de Paris | College/University | Masters Business Admin | |
London School of Economics & Political Science | College/University | Masters Business Admin | |
University of Ljubljana | College/University | Undergraduate Degree | |
Elucida Oncology, Inc.
Elucida Oncology, Inc. BiotechnologyHealth Technology Elucida Oncology, Inc. operates as a biotechnology company which focuses on clinical research and development. The company was founded by Isaac Blech, Michelle Bradbury, Ulrich Weisner, and Steven Larson in 2014 and is headquartered in Monmouth Junction, NJ. | Biotechnology | Director/Board Member |
Statistik
International
Vereinigte Staaten | 30 |
Vereinigtes Königreich | 9 |
Slowenien | 6 |
Deutschland | 3 |
Frankreich | 2 |
Sektoral
Health Technology | 17 |
Consumer Services | 14 |
Finance | 13 |
Health Services | 2 |
Miscellaneous | 2 |
Operativ
Director/Board Member | 191 |
Corporate Officer/Principal | 107 |
Undergraduate Degree | 81 |
Independent Dir/Board Member | 54 |
Analyst-Equity | 41 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Martin Edwards | 38 |
Mahendra Shah | 34 |
Rishi Gupta | 29 |
Ben Harber | 29 |
David Ebsworth | 26 |
Chris Burggraeve | 20 |
Sven Anders Ullman | 19 |
Sean Nolan | 18 |
J. Goater | 17 |
Ken Cunningham Cunningham | 17 |
Frank Verwiel | 16 |
Christina Ackermann | 15 |
Philip Donenberg | 15 |
Amber Salzman | 14 |
Mark Hahn | 13 |
- Börse
- Insiders
- Lisa Deschamps
- Unternehmensverbindungen